AC Immune (ACIU) Downgraded by BidaskClub to “Buy”

BidaskClub downgraded shares of AC Immune (NASDAQ:ACIU) from a strong-buy rating to a buy rating in a research note issued to investors on Monday morning, BidAskClub reports.

Several other research firms have also recently weighed in on ACIU. Zacks Investment Research raised AC Immune from a hold rating to a buy rating and set a $4.50 price objective for the company in a research report on Wednesday, February 6th. UBS Group cut AC Immune from a buy rating to a neutral rating in a research report on Friday, February 1st. HC Wainwright reissued a buy rating and issued a $18.00 price objective on shares of AC Immune in a research report on Thursday, January 24th. Finally, ValuEngine cut AC Immune from a hold rating to a sell rating in a research report on Monday, March 25th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $11.94.

Shares of AC Immune stock opened at $4.85 on Monday. The company has a market cap of $327.68 million, a price-to-earnings ratio of -5.91 and a beta of 0.01. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.06 and a quick ratio of 5.06. AC Immune has a 12-month low of $3.25 and a 12-month high of $17.40.

AC Immune (NASDAQ:ACIU) last announced its earnings results on Wednesday, May 15th. The company reported $0.84 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.36). The company had revenue of $75.28 million for the quarter, compared to the consensus estimate of $106.81 million. AC Immune had a return on equity of 12.17% and a net margin of 29.66%. As a group, equities analysts predict that AC Immune will post 0.69 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Alps Advisors Inc. bought a new stake in shares of AC Immune in the fourth quarter valued at approximately $1,471,000. BlackRock Inc. bought a new stake in shares of AC Immune in the fourth quarter valued at approximately $6,092,000. FMR LLC boosted its position in shares of AC Immune by 7.7% in the fourth quarter. FMR LLC now owns 5,612,759 shares of the company’s stock valued at $53,039,000 after acquiring an additional 403,086 shares during the period. Virtu Financial LLC bought a new stake in shares of AC Immune in the first quarter valued at approximately $397,000. Finally, Marshall Wace LLP bought a new stake in shares of AC Immune in the third quarter valued at approximately $107,000. 22.99% of the stock is owned by institutional investors.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Featured Story: Outstanding Shares

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.